Home › Funds › Trium Capital LLP › ALMS
Trium Capital LLP position in ALMS
ALUMIS INC · Health Care
Trium Capital LLP reported holding 200,773 shares of ALMS (ALUMIS INC) in its Q3 2026 13F filing — a position valued at US$1.5M, representing 1.87% of its reported portfolio and ranking #8 among its reported holdings. Trium Capital LLP has disclosed ALMS holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-10-16 · Source: SEC EDGAR Form 13F-HR
How Trium Capital LLP's ALMS position evolved
Trium Capital LLP first disclosed a stake in ALMS in Q2 2025 at 2,648,039 shares (US$7.9M). The position peaked in Q3 2025 at 3,122,111 shares, worth US$12.5M. Across 6 filings, Trium Capital LLP increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 200,773 shares valued at US$1.5M — a reduction of -189,495 shares quarter over quarter.. Notable position changes include a 71% trim in Q4 2025 (shares rose 126% over the following quarter), a 79% trim in Q1 2026 (shares rose 28% over the following quarter), a 104% increase in Q2 2026 (shares fell 74% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 2.65M | $7.94M | New |
| Q3 2025 | 3.12M | $12.46M | Add |
| Q4 2025 | 893.11K | $8.72M | Reduce |
| Q1 2026 | 191.39K | $4.22M | Reduce |
| Q2 2026 | 390.27K | $10.98M | Add |
| Q3 2026 | 200.77K | $1.48M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALMS and 13F data
ALMS (ALUMIS INC) is a Health Care company. 89 other funds we track also report a position in ALMS — the largest reported positions include AyurMaya Capital Management Company, LP (US$426.0M), Deep Track Capital, LP (US$178.6M), Samsara BioCapital, LLC (US$178.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALMS
- AyurMaya Capital Management Company, LP 15.14M sh · $426.03M · Q2 2026
- Deep Track Capital, LP 6.35M sh · $178.65M · Q2 2026
- Samsara BioCapital, LLC 6.35M sh · $178.55M · Q2 2026
- Foresite Capital Management V, LLC 5.90M sh · $165.94M · Q2 2026
- venBio Partners LLC 4.53M sh · $127.43M · Q2 2026
- Foresite Capital Management VI LLC 4.25M sh · $119.53M · Q2 2026
- Nextech Invest Ltd. 3.54M sh · $99.64M · Q2 2026
- Cormorant Asset Management, LP 3.29M sh · $92.46M · Q2 2026
- Saturn V Capital Management LP 2.92M sh · $82.04M · Q2 2026
- Octagon Capital Advisors LP 2.83M sh · $79.66M · Q2 2026
- MPM BioImpact LLC 2.02M sh · $56.82M · Q2 2026
- BAKER BROS. ADVISORS LP 2.01M sh · $56.63M · Q2 2026
More on Trium Capital LLP
FAQ
How long has Trium Capital LLP held ALMS?
Trium Capital LLP has disclosed ALMS holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Trium Capital LLP's current position in ALMS?
As of Q3 2026, Trium Capital LLP holds 200.77K shares of ALMS (ALUMIS INC), valued at $1.48M, representing 1.87% of its reported portfolio and ranking #8.
Has Trium Capital LLP been buying or selling ALMS?
In the latest 13F filing (Q3 2026), Trium Capital LLP reduced its position in ALMS. The position peaked in Q3 2025 at 3.12M shares.
Which other funds hold ALMS?
Other major institutional holders of ALMS include AyurMaya Capital Management Company, LP, Deep Track Capital, LP, Samsara BioCapital, LLC, among 89 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.